# Mechanical Evidence Recheck

## Scope and method

This artifact records a fresh mechanical recheck of every stable candidate ID C001 through C016 against the exact supplied PDF pages. The original PDFs were the final authority. Reusable text and mapping artifacts were used only to locate evidence. Targeted page-level layout extraction and visual rendering from the original PDFs were written under `preprocessing/recheck/`; no source or reused artifact was modified. The records below are evidence facts for human adjudication, not AI dispositions.

## C001 — Placebo discontinuation counts differ between Figure 1 and the Results text

- **Cited location found:** Yes. [Main PDF p. 3, Figure 1](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=3>) and [Main PDF p. 7, Results](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=7>) were found in the supplied article.
- **Source printed value or text matched:** Yes. Figure 1 prints 132 randomized to placebo, 111 completing 24 weeks of placebo treatment, and 21 discontinuing; the 21 comprise 8 adverse events, 6 lack of efficacy, 6 could not be contacted, and 1 withdrew consent.
- **Comparator printed value or text matched:** Yes. Results prints that 40 participants withdrew or were lost to follow-up, including 17 in the krill-oil group and 23 in the placebo group, and that 222 completed the trial.
- **Consistency rule applicable:** The exact randomized-arm identity is applicable within each display. Comparing the two displays as the same completion disposition is applicable only if “discontinued” and “withdrew or were lost to follow-up” cover the same participants and “completed 24 weeks of treatment” and “completed the trial” use the same completion definition.
- **Calculation or logical comparison reproduced:** Figure 1 gives `111 + 21 = 132`, `113 + 111 = 224` completers, and `17 + 21 = 38` discontinuations. Results gives `17 + 23 = 40` withdrawals or losses and 222 completers; using the randomized placebo count gives `132 - 23 = 109`, not 111.
- **Necessary inputs available:** The randomized arm sizes and all compared counts are available.
- **Exact missing inputs or definitions:** The package does not define whether “discontinued,” “withdrew or were lost to follow-up,” “completed 24 weeks of treatment,” and “completed the trial” are identical disposition categories, nor does it identify two additional placebo participants outside Figure 1's 21 discontinuations.
- **Source-grounded alternative interpretation:** The Results category may include two placebo participants who are not classified as discontinued in Figure 1, or one display may contain a transcription difference.
- **Direct observation versus inferred explanation:** The printed 21 versus 23, 224 versus 222, and 38 versus 40 counts are direct observations. Category equivalence and any omitted-participant or transcription explanation are inferences.
- **Exact remaining human question:** Do the 23 placebo withdrawals or losses include two participants outside Figure 1's 21 discontinuations, and, if so, what are their Figure 1 dispositions and why does Figure 1 still print 111 placebo completers?

## C002 — eTable 2 names 167 and 165 for the overall adherence population

- **Cited location found:** Yes. [Supplement 3 PDF p. 3, eTable 2](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=3>) was found.
- **Source printed value or text matched:** Yes. The overall 0-to-24-week row prints `n = 167`, krill oil `82 (98.8)`, and placebo `81 (96.4)`.
- **Comparator printed value or text matched:** Yes. The footnote prints that adherence was calculated for participants with available pill-count data who completed the trial, `n = 165 [75%]`.
- **Consistency rule applicable:** A table row total and a footnote population count should agree if the footnote defines the population used for that row. One-decimal percentage reconciliation is also applicable to the printed count/percentage pairs.
- **Calculation or logical comparison reproduced:** `82/83 × 100 = 98.7952%`, which displays as 98.8%, and `81/84 × 100 = 96.4286%`, which displays as 96.4%; `83 + 84 = 167`. The row-supported total is therefore two larger than 165.
- **Necessary inputs available:** The overall row total, adherent counts, percentages, and footnote total are available.
- **Exact missing inputs or definitions:** The table does not print the arm-specific overall denominators explicitly or define a narrower population represented by 165. It does not explain how 165 relates to the row total of 167.
- **Source-grounded alternative interpretation:** The footnote's 165 may describe a narrower unlabelled subset, while 167 is the row analysis population; alternatively, the footnote may be stale relative to the row.
- **Direct observation versus inferred explanation:** The values 167, 82, 98.8%, 81, 96.4%, and 165 are direct observations. Denominators 83 and 84 are inferred by exact integer percentage reconciliation with the printed total. A narrower subset or stale footnote is an inferred explanation.
- **Exact remaining human question:** What precise participant set does footnote `n = 165` denote, and why does it differ from the overall row's `n = 167` supported by its two printed count/percentage cells?

## C003 — eTable 5 krill “Smaller by 1 unit” percentage conflicts with 10 of 107

- **Cited location found:** Yes. [Supplement 3 PDF p. 8, eTable 5](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=8>) was found.
- **Source printed value or text matched:** Yes. The krill-oil `Smaller - 1 unit` cell prints `10 (12%)`.
- **Comparator printed value or text matched:** Yes. The same krill-oil column prints `Total 107 (100%)`.
- **Consistency rule applicable:** A category percentage should equal its printed count divided by its printed arm total, subject to the table's whole-percentage display precision.
- **Calculation or logical comparison reproduced:** `10/107 × 100 = 9.3458%`, which rounds to 9% at whole-percent precision, not 12%.
- **Necessary inputs available:** The category count, printed percentage, and arm total are available.
- **Exact missing inputs or definitions:** No alternative denominator is printed for this category.
- **Source-grounded alternative interpretation:** The 12% may use an unreported denominator, or the count, percentage, or total may reflect a different table version.
- **Direct observation versus inferred explanation:** `10 (12%)` and total 107 are direct observations. The 9.3458% calculation is derived. Any unreported denominator or version difference is inferred.
- **Exact remaining human question:** Is the count 10, the percentage 12%, or the displayed krill-oil total 107 the intended value for this category?

## C004 — eTable 5 krill “No change” percentage conflicts with 80 of 107

- **Cited location found:** Yes. [Supplement 3 PDF p. 8, eTable 5](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=8>) was found.
- **Source printed value or text matched:** Yes. The krill-oil `No change` cell prints `80 (72%)`.
- **Comparator printed value or text matched:** Yes. The krill-oil total prints `107 (100%)`.
- **Consistency rule applicable:** A category percentage should reproduce from the category count and arm total at whole-percent precision.
- **Calculation or logical comparison reproduced:** `80/107 × 100 = 74.7664%`, which rounds to 75%, not 72%.
- **Necessary inputs available:** The category count, percentage, and arm total are available.
- **Exact missing inputs or definitions:** No category-specific alternative denominator is supplied.
- **Source-grounded alternative interpretation:** The 72% may use an unreported denominator, or one of the displayed count, percentage, or total may come from a different table version.
- **Direct observation versus inferred explanation:** The displayed cells are direct observations; 74.7664% is derived. An alternate denominator or version is inferred.
- **Exact remaining human question:** Which of 80, 72%, or total 107 was intended to define the krill-oil no-change category?

## C005 — eTable 5 krill “Larger by 1 unit” percentage conflicts with 12 of 107

- **Cited location found:** Yes. [Supplement 3 PDF p. 8, eTable 5](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=8>) was found.
- **Source printed value or text matched:** Yes. The krill-oil `Larger - 1 unit` cell prints `12 (12%)`.
- **Comparator printed value or text matched:** Yes. The krill-oil total prints `107 (100%)`.
- **Consistency rule applicable:** The displayed category percentage should reproduce from its count and arm total at whole-percent precision.
- **Calculation or logical comparison reproduced:** `12/107 × 100 = 11.2150%`, which rounds to 11%, not 12%.
- **Necessary inputs available:** The count, percentage, and arm total are available.
- **Exact missing inputs or definitions:** No alternative denominator is printed for this category.
- **Source-grounded alternative interpretation:** A different unreported denominator could produce 12%, or a displayed cell may come from a different table version.
- **Direct observation versus inferred explanation:** `12 (12%)` and total 107 are direct observations; 11.2150% is derived. The alternative denominator or version explanation is inferred.
- **Exact remaining human question:** Was another denominator used, or should the percentage be reconciled to 12 of 107?

## C006 — eTable 5 placebo “Smaller by 2 units” percentage conflicts with 2 of 109

- **Cited location found:** Yes. [Supplement 3 PDF p. 8, eTable 5](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=8>) was found.
- **Source printed value or text matched:** Yes. The placebo `Smaller - 2 units` cell prints `2 (1.9%)`.
- **Comparator printed value or text matched:** Yes. The placebo total prints `109 (100%)`.
- **Consistency rule applicable:** The displayed one-decimal percentage should reproduce from its count and arm total within one-decimal rounding.
- **Calculation or logical comparison reproduced:** `2/109 × 100 = 1.8349%`, which rounds to 1.8% at one decimal, not 1.9%.
- **Necessary inputs available:** The count, percentage, and arm total are available.
- **Exact missing inputs or definitions:** No alternative denominator is printed for this category.
- **Source-grounded alternative interpretation:** A smaller unreported denominator could display as 1.9%, or the printed percentage may reflect different rounding inputs or a transcription difference.
- **Direct observation versus inferred explanation:** `2 (1.9%)` and total 109 are direct observations; 1.8349% is derived. Another denominator or transcription mechanism is inferred.
- **Exact remaining human question:** Was a denominator other than 109 used for this placebo category, or is the displayed 1.9% based on different underlying inputs?

## C007 — eTable 5 placebo “Smaller by 1 unit” percentage conflicts with 16 of 109

- **Cited location found:** Yes. [Supplement 3 PDF p. 8, eTable 5](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=8>) was found.
- **Source printed value or text matched:** Yes. The placebo `Smaller - 1 unit` cell prints `16 (12%)`.
- **Comparator printed value or text matched:** Yes. The placebo total prints `109 (100%)`.
- **Consistency rule applicable:** The displayed category percentage should reproduce from its count and arm total at whole-percent precision.
- **Calculation or logical comparison reproduced:** `16/109 × 100 = 14.6789%`, which rounds to 15%, not 12%.
- **Necessary inputs available:** The count, percentage, and arm total are available.
- **Exact missing inputs or definitions:** No alternative denominator is supplied.
- **Source-grounded alternative interpretation:** A denominator near 133 could yield about 12%, but that would not be the displayed arm total of 109; alternatively, a count or percentage may have been carried from another table version.
- **Direct observation versus inferred explanation:** The printed values are direct observations; 14.6789% is derived. An alternate denominator or version difference is inferred.
- **Exact remaining human question:** Which of the count 16, percentage 12%, or placebo total 109 was intended for this category?

## C008 — eTable 5 placebo “No change” percentage conflicts with 75 of 109

- **Cited location found:** Yes. [Supplement 3 PDF p. 8, eTable 5](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=8>) was found.
- **Source printed value or text matched:** Yes. The placebo `No change` cell prints `75 (72%)`.
- **Comparator printed value or text matched:** Yes. The placebo total prints `109 (100%)`.
- **Consistency rule applicable:** The displayed category percentage should reproduce from its count and arm total at whole-percent precision.
- **Calculation or logical comparison reproduced:** `75/109 × 100 = 68.8073%`, which rounds to 69%, not 72%.
- **Necessary inputs available:** The count, percentage, and arm total are available.
- **Exact missing inputs or definitions:** No separate denominator is printed for this category.
- **Source-grounded alternative interpretation:** A denominator near 104 could yield approximately 72%, or one displayed cell may reflect another table version.
- **Direct observation versus inferred explanation:** The printed values are direct observations; 68.8073% is derived. An alternative denominator or version difference is inferred.
- **Exact remaining human question:** Is 72% based on another population, or should the placebo no-change percentage reconcile to 75 of 109?

## C009 — eTable 4 repeats week-4 function changes in the weight-bearing-pain row

- **Cited location found:** Yes. [Supplement 3 PDF p. 5, eTable 4](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=5>) was found.
- **Source printed value or text matched:** Yes. Week-4 weight-bearing pain prints krill final 100, baseline 127, and change `-84 (-122 to -46)`; it prints placebo final 108, baseline 141, and change `-103 (-141 to -65)`.
- **Comparator printed value or text matched:** Yes. The adjacent week-4 Function row prints the identical krill and placebo change pairs, `-84 (-122 to -46)` and `-103 (-141 to -65)`.
- **Consistency rule applicable:** Exact paired estimate-and-interval repetition across separately labelled outcomes with different scales is an applicable duplicated-value check. Simple final-minus-baseline arithmetic is only diagnostic because the source describes model-derived changes and baseline adjustment for weight-bearing pain.
- **Calculation or logical comparison reproduced:** The two change estimate/interval pairs match character for character. Descriptive subtraction gives `100 - 127 = -27` and `108 - 141 = -33`, not -84 and -103. For the function row, the corresponding descriptive differences are `493 - 578 = -85` and `503 - 618 = -115`, which are much closer to the duplicated change values but are not substituted for model estimates.
- **Necessary inputs available:** The labels, final values, baseline values, arm changes, intervals, table adjustment note, and adjacent function-row comparator are available.
- **Exact missing inputs or definitions:** The exact cell-level estimand mapping, model output, covariance specification, and table-production source are absent.
- **Source-grounded alternative interpretation:** The modelled weight-bearing changes could differ from raw subtraction, and exact equality with the function row could be coincidental; the supplied table gives no definition explaining the duplicated pair.
- **Direct observation versus inferred explanation:** The repeated printed estimates and intervals are direct observations. Raw subtraction is a diagnostic calculation. Copying, transposition, coincidence, or an unlabelled estimand is inferred.
- **Exact remaining human question:** Were the week-4 weight-bearing-pain arm-change cells copied from the function row, and what arm-change values and intervals appear in the source analysis output?

## C010 — eTable 4 repeats week-4 back-pain results in week-12 lower-leg strength

- **Cited location found:** Yes. [Supplement 3 PDF p. 6, eTable 4](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=6>) was found.
- **Source printed value or text matched:** Yes. Week-12 lower-leg strength prints krill change `-2.8 (-6.0 to 0.4)`, placebo change `-4.2 (-7.4 to -1.1)`, between-group result `-1.4 (-5.9 to 3.0)`, and `P = 0.53`.
- **Comparator printed value or text matched:** Yes. Week-4 back-pain VAS prints the same two arm changes, the same between-group estimate and interval, and the same P value.
- **Consistency rule applicable:** Exact repetition of the complete inferential result and both arm-change results across outcomes with different labels, scales, and directions is an applicable duplicated-value check. Raw final-minus-baseline subtraction is diagnostic only.
- **Calculation or logical comparison reproduced:** Every displayed arm-change estimate/interval and between-group estimate/interval/P field matches exactly. Descriptive strength subtraction gives `72.6 - 66.5 = +6.1` and `70.2 - 65.9 = +4.3`, unlike the printed negative arm changes.
- **Necessary inputs available:** Both outcome labels, time points, final and baseline values, arm changes, intervals, between-group results, and P values are available.
- **Exact missing inputs or definitions:** The source analysis output, exact cell-level estimand mapping, covariance structure, and table-production history are not supplied.
- **Source-grounded alternative interpretation:** A modelled strength change may differ from descriptive subtraction, and complete equality with the back-pain output is mathematically possible; the source does not explain why all printed result fields are identical.
- **Direct observation versus inferred explanation:** Exact repetition is directly observed. Descriptive subtraction is diagnostic. Copying, row displacement, or coincidence is inferred.
- **Exact remaining human question:** Do the week-12 lower-leg-strength cells belong to strength, and what are the intended arm changes, between-group estimate, interval, and P value in the source output?

## C011 — eTable 4 repeats the week-12 hsCRP result in fasting glucose

- **Cited location found:** Yes. [Supplement 3 PDF p. 6, eTable 4](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=6>) was found.
- **Source printed value or text matched:** Yes. Week-12 fasting glucose prints arm changes `0.09 (-0.07 to 0.24)` and `0.15 (-0.01 to 0.31)`, followed by `0.07 (-1.19 to 1.33)` and `P = 0.92`.
- **Comparator printed value or text matched:** Yes. The week-12 high-sensitivity C-reactive protein row also prints between-group `0.07 (-1.19 to 1.33)` and `P = 0.92`, while its arm changes are `-0.53 (-1.32 to 0.26)` and `0.24 (-0.55 to 1.03)`.
- **Consistency rule applicable:** Exact estimate/interval/P repetition across two separately labelled measures with different arm-level results is an applicable duplicated-value and measure-label check. Arm-change subtraction is diagnostic only.
- **Calculation or logical comparison reproduced:** The three between-group fields match exactly. The displayed fasting-glucose arm changes differ by `0.09 - 0.15 = -0.06`, whereas the printed between-group point estimate is +0.07; this does not reconstruct the adjusted model.
- **Necessary inputs available:** The endpoint labels, arm changes and intervals, and both between-group results and P values are available.
- **Exact missing inputs or definitions:** The exact model estimand mapping, adjustment calculation, variance specification, source output, and table-production history are absent.
- **Source-grounded alternative interpretation:** A separately modelled glucose result could differ from arm-change subtraction, and exact equality with hsCRP is possible; no supplied definition explains equality of the estimate, interval, and P value across the two measures.
- **Direct observation versus inferred explanation:** The duplicated result fields are direct observations. The -0.06 subtraction is diagnostic. Copying or coincidence is inferred.
- **Exact remaining human question:** Does the printed week-12 between-group cell belong to fasting glucose, and what estimate, interval, and P value appear in the source glucose analysis output?

## C012 — Key Points and other matched primary-result displays use opposite signs

- **Cited location found:** Yes. [Main PDF p. 2, Key Points](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=2>), [Main PDF p. 1, Abstract](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=1>), [Main PDF p. 6, Table 2](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=6>), [Main PDF p. 7, Results](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=7>), and [Supplement 3 PDF p. 2, eTable 1](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=2>) were found.
- **Source printed value or text matched:** Yes. Key Points prints mean difference `0.30`, 95% CI `-6.9 to 6.4`, and `P = .94` over 24 weeks.
- **Comparator printed value or text matched:** Yes. The Abstract, Table 2, and Results print `-0.3` for the same 24-week primary result; Table 2 and Results also print the same interval and `P = .94`. eTable 1 original data prints `-0.27 (-6.92 to 6.38)`, `P = 0.94`.
- **Consistency rule applicable:** Otherwise matched repeated displays should identify a signed operand order or consistently label an unsigned magnitude; the package does neither while printing opposite signs.
- **Calculation or logical comparison reproduced:** Rounding -0.27 to one decimal produces -0.3, not +0.30. The repeated interval and P value support identity of the result across locations.
- **Necessary inputs available:** The endpoint, 24-week time point, arm changes, repeated point estimates, intervals, and P values are available.
- **Exact missing inputs or definitions:** The source does not define a common signed operand order, whether Key Points is an unsigned magnitude, or the production history of the sign displays.
- **Source-grounded alternative interpretation:** Key Points may intend an unsigned magnitude, another location may use an unstated opposite operand order, or a sign may have been lost in production.
- **Direct observation versus inferred explanation:** The positive-versus-negative sign difference and matching surrounding fields are direct observations. Any common orientation, absolute-value intent, or lost sign is inferred.
- **Exact remaining human question:** What signed contrast orientation was intended in each location, and was Key Points intended as an absolute magnitude or a signed difference?

## C013 — Placebo extremity-pain event count is 6 in Table 3 and 5 elsewhere

- **Cited location found:** Yes. [Main PDF p. 1, Abstract](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=1>), [Main PDF p. 8, Table 3 and narrative](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=8>), and [Supplement 3 PDF p. 10, eTable 7](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=10>) were found.
- **Source printed value or text matched:** Yes. Table 3 prints `Pain in extremity` as 1 event for krill oil and 6 for placebo.
- **Comparator printed value or text matched:** Yes. The Abstract and p. 8 narrative print lower-extremity pain as 1 event for krill oil and 5 for placebo. eTable 7 prints `Pain in extremity` as 1 and 5.
- **Consistency rule applicable:** Exact event counts should agree across repeated reports if `lower extremity pain` and `Pain in extremity` represent the same event category and aggregation.
- **Calculation or logical comparison reproduced:** The krill count is 1 in all locations; the placebo count is 6 in Table 3 and 5 in each of the other three printed occurrences. The exact integer difference is one event.
- **Necessary inputs available:** The group labels, event labels, integer counts, surrounding matched knee/hip categories, and eTable 7 reference are available.
- **Exact missing inputs or definitions:** The adverse-event coding dictionary and any definition distinguishing `lower extremity pain` from `Pain in extremity` are not supplied.
- **Source-grounded alternative interpretation:** The two phrasings could represent different coding aggregates, although eTable 7 uses the same wording as Table 3 and prints 5; alternatively, Table 3 may contain a transcription difference.
- **Direct observation versus inferred explanation:** The 6-versus-5 difference is directly printed. Category identity, aggregation differences, and transcription are inferred explanations.
- **Exact remaining human question:** Does Table 3 use a distinct adverse-event aggregate that includes one additional placebo event, or should its placebo `Pain in extremity` count match the 5 printed in the Abstract, narrative, and eTable 7?

## C014 — Table 3 regular-adverse-event footnote points to eTable 4 instead of eTable 7

- **Cited location found:** Yes. [Main PDF p. 8, Table 3 footnote a and narrative](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=8>), [Supplement 3 PDF p. 5, eTable 4](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=5>), and [Supplement 3 PDF p. 10, eTable 7](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=10>) were found.
- **Source printed value or text matched:** Yes. Table 3 footnote a states that detailed information is provided in eTable 4 in Supplement 3.
- **Comparator printed value or text matched:** Yes. The p. 8 narrative cites eTable 7 for common adverse events. Supplement eTable 4 is titled `Change in secondary endpoints between krill oil and placebo groups`; eTable 7 is titled `Summary of adverse events during the study per treatment group (n)`.
- **Consistency rule applicable:** A cross-reference described as the location of detailed adverse-event information should point to a supplied table containing adverse-event detail.
- **Calculation or logical comparison reproduced:** Logical header/content matching shows that eTable 4 is a secondary-endpoint time-series table and eTable 7 is the detailed adverse-event table named by the narrative.
- **Necessary inputs available:** The exact footnote, narrative reference, table numbers, titles, and contents are available.
- **Exact missing inputs or definitions:** The supplement's production-version history and any earlier table-numbering scheme are absent.
- **Source-grounded alternative interpretation:** Footnote a may retain an earlier supplement table number after renumbering.
- **Direct observation versus inferred explanation:** The footnote destination, narrative destination, and supplied table titles are direct observations. Stale renumbering is inferred.
- **Exact remaining human question:** Which supplied eTable number was intended in Table 3 footnote a as the destination for detailed regular adverse-event information?

## C015 — Table 3 serious-adverse-event footnote points to eTables 5 and 6 instead of eTable 8

- **Cited location found:** Yes. [Main PDF p. 8, Table 3 footnote c and narrative](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=8>), [Supplement 3 PDF p. 8, eTable 5](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=8>), [Supplement 3 PDF p. 9, eTable 6](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=9>), and [Supplement 3 PDF p. 14, eTable 8](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=14>) were found.
- **Source printed value or text matched:** Yes. Table 3 footnote c states that comprehensive serious-adverse-event details can be found in eTables 5 and 6 in Supplement 3.
- **Comparator printed value or text matched:** Yes. The p. 8 narrative points to eTable 8 for the 9 krill-oil and 6 placebo serious events. eTable 5 is the WORMS effusion-score change table; eTable 6 is the analgesic-use table; eTable 8 is titled `Summary of serious adverse events during the study per treatment group (relationship with treatment)`.
- **Consistency rule applicable:** A cross-reference described as the location of comprehensive serious-adverse-event detail should point to a supplied table containing serious-event information.
- **Calculation or logical comparison reproduced:** Logical header/content matching shows that neither eTable 5 nor eTable 6 contains serious-event detail, while eTable 8 does and is cited by the narrative.
- **Necessary inputs available:** The exact footnote, narrative reference, table numbers, headers, and contents are available.
- **Exact missing inputs or definitions:** The supplement's production-version history and any prior numbering scheme are absent.
- **Source-grounded alternative interpretation:** Footnote c may retain table numbers from an earlier supplement layout.
- **Direct observation versus inferred explanation:** The cross-references and table subjects are direct observations. Renumbering or an uncorrected internal reference is inferred.
- **Exact remaining human question:** Which supplied eTable reference was intended in Table 3 footnote c for comprehensive serious-adverse-event details?

## C016 — Main-text 95% adherence does not reproduce the cited eTable 2 overall result

- **Cited location found:** Yes. [Main PDF p. 7, Process Measures](<../../../jama_laslett_2024_oi_240048_1727199125.7595.pdf#page=7>) and [Supplement 3 PDF p. 3, eTable 2](<../../../joi240048supp3_prod_1727199125.83025.pdf#page=3>) were found.
- **Source printed value or text matched:** Yes. The main text prints that 95% of participants consumed at least 80% of softgels over the 24-week study period and cites eTable 2.
- **Comparator printed value or text matched:** Yes. The eTable 2 overall 0-to-24-week row prints `n = 167`, krill oil `82 (98.8)`, and placebo `81 (96.4)` for consumption of at least 80% of study treatment. Its footnote separately prints `n = 165 [75%]` for available pill-count data and trial completers.
- **Consistency rule applicable:** A narrative pooled percentage should reproduce from its cited table when the threshold, period, and participant population match. Applicability to an exact common population remains conditional because the narrative denominator is not printed and the eTable itself names both 167 and 165.
- **Calculation or logical comparison reproduced:** The displayed adherent counts sum to `82 + 81 = 163`; `163/167 × 100 = 97.6048%`, which displays as 97.6% at one decimal or 98% at whole-percent precision, not 95%.
- **Necessary inputs available:** The narrative percentage, threshold, period, citation, table row total, arm counts, and arm percentages are available.
- **Exact missing inputs or definitions:** The numerator and denominator used for the narrative 95% are absent. The source does not define how the row's 167 and footnote's 165 relate or whether the main text used either population.
- **Source-grounded alternative interpretation:** The main-text 95% may use an unstated subset or an earlier table version; the cited table may have been updated without corresponding narrative revision.
- **Direct observation versus inferred explanation:** The narrative 95%, table counts/percentages, 167, and footnote 165 are direct observations. The pooled 97.6048% is derived. An unstated subset or version mismatch is inferred.
- **Exact remaining human question:** What numerator and denominator produced the main-text 95%, and how do they reconcile with the cited eTable 2 row's 163 of 167 and the footnote's separate `n = 165`?

## Recheck completion summary

All cited locations for C001 through C016 were found in the supplied PDFs, and every ledger source value and comparator was matched. All stated arithmetic or logical comparisons were reproduced. The unresolved items are the exact disposition-category definitions for C001; adherence population and denominator definitions for C002 and C016; unreported category denominators for C003 through C008; source model outputs and table-production mappings for C009 through C011; editorial intent for C012; adverse-event coding aggregation for C013; and production numbering history for C014 and C015. These remaining questions require human or source-production evidence not present in the supplied package.
